Stevanato Group Investor Relations

Founded in 1949, Stevanato Group is a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. The Group delivers an integrated, end-to-end portfolio of products, processes and services that address customer needs across the entire drug life cycle at each of the development, clinical and commercial stages. Stevanato Group’s core capabilities in scientific research and development, its commitment to technical innovation and its engineering excellence are central to its ability to offer value added solutions to clients.

Latest News

Stevanato Group Reports Financial Results for the Third Quarter of 2024

View Press Release

Stevanato Group to Report Third Quarter 2024 Financial Results on November 5, 2024

View Press Release

Stevanato Group Will Introduce Its Large-Volume Vertiva® 10mL On-Body Delivery System Platform for Injectable Therapies at CPHI Milan

View Press Release

Stevanato Group, Gerresheimer and SCHOTT Pharma, Announce Strategic Industry “Alliance for RTU”

View Press Release

Latest Financial Results

Q3 2024

Quarter Ended Sep 30, 2024

Earnings Release
PDF HTML
Audio
Earnings Webcast
Prepared Comments
PDF

We respect your privacy. We do not sell, rent, or loan any information to any third party.
Any information you give us is held with the utmost care and security, and will be used
only in ways indicated in our Privacy Policy.

Latest Annual Filing

For Fiscal Year Ending Dec 31, 2023

Report Links

IR Contacts

Company

Stevanato Group S.p.A.
Via Molinella 17
Piombino Dese, Padua 35017
Italy

Investor Relations

Lisa Miles
Senior Vice President, Investor Relations
lisa.miles@stevanatogroup.com

Transfer Agent

Computershare Trust Company, N.A.
150 Royall Street
Canton, MA 02021